

Supplementary Figure 4. KRAS effectors activate CREB1 through its phosphorylation at serine 133. A, PDAC cells were treated with a MEK inhibitor (trametinib), a PI3K inhibitor (pictilisib) and a PKA inhibitor (H89) to determine the effect of major KRAS effectors on p-CREB1^{S133} levels. **B,** The effect of EGF treatment on p-CREB1^{S133} levels. **C,** The effect of pharmacologic MEK inhibition with AZD6244 or U0126 (MEK inhibitors) on p-CREB1^{S133} levels, with and without EGF stimulation. **D,** The effect of EGF treatment on p-CREB1^{S133} and FOXA1 levels in the presence and absence of oncogenic *KRAS* knockdown. **E,** The effect of PDGF treatment on p-CREB1^{S133} and FOXA1 levels in the presence and absence of oncogenic *KRAS* knockdown. **(D, E),** P value calculated by one-way ANOVA.